-
-
-
-
-
-
-
Gilead Sciences Exercises Option to License Assembly Biosciences’ Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
-
-
-
-
-
-
-
Assembly Biosciences (ASMB) Misses Q3 EPS by 151c
-
-
-
-
-
-
-
Assembly Biosciences, Inc. (ASMB) Misses Q3 EPS by 3c
-
-
-
-
-
-
-
Assembly Biosciences (ASMB) Provides Update on its Core Inhibitor Pipeline, Reports Q4
-
-
-
-
-
-
-
Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
-
-
-
-
-
-
-
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
-
1,222,612 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

